Testing a new pill for sickle cell disease safety
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have sickle cell anemia (HbSS or HbS beta-zero thalassemia), confirmed by a blood test.
- You must not have had a blood transfusion in the last 60 days.
- You must have adequate liver, kidney, and blood cell counts (your doctor will check this).
- If you take hydroxyurea for sickle cell, your dose must have been stable for at least 3 months.
- You must agree to use effective contraception (or be abstinent) during the study and for 28 days after the last dose.
- You must not have had a pain crisis requiring IV treatment in the last 14 days.
- You must not have had a bone marrow or stem cell transplant.
- You must not be pregnant or breastfeeding.
- You must not have taken the study drug (fostamatinib) in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests a drug that helps your body release stem cells so they can be collected for a future bone marrow transplant. It may help make the transplant process safer and more effective for people with sickle cell disease.
This early-phase study tests panobinostat, a medicine aimed at reducing sickle-cell problems, in adults with severe disease. It’s mainly looking at safety and whether it can improve blood-related issues that drive pain and complications.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This trial tests a gene therapy that uses a modified virus to deliver a healthy gene to your blood stem cells. It aims to help people with sickle cell disease produce normal red blood cells and reduce painful crises.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.